About Replimune Group, Inc.
Replimune is a clinical-stage biotech developing oncolytic immunotherapies for cancer. Low beta historically but extreme binary event risk around FDA decisions. No dividend. CSP selling near PDUFA dates is essentially a coin flip — only for aggressive biotech-aware sellers.
Biotechnology